Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

Autor: Julia del Amo, Polo, Rosa, Moreno, Santiago, Berenguer, Juan, Martínez, Esteban, Hernán, Miguel, Martínez de Salazar, Pablo, García de Albéniz, Xabier, García-Albéniz, Xabier, Terán, Carolina, Morales, Miguel, Rial-Crestelo, David, Garcinuño, M. Angeles, García del Toro, Miguel, Hita, César, Gómez-Sirvent, Juan Luis, Buzón, Luis, Díaz de Santiago, Alberto, Arellano, Jose Pérez, Sanz, Jesus, Bachiller, Pablo, Alfaro, Elisa Martínez, Díaz-Brito, Vicente, Masiá, Mar, Hernández-Torres, Alicia, Guerra, Jose M., Santos, Jesús, Arazo, Piedad, Muñoz, Leopoldo, Arribas, Jose Ramon, Hernán, Miguel A., Del Amo, Julia

Publikováno v: In Clinical Microbiology and Infection January 2023 29(1):85-93

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

Autor: De Miguel, Rosa, Rial-Crestelo, David, Dominguez-Dominguez, Lourdes, Montejano, Rocío, Esteban-Cantos, Andrés, Aranguren-Rivas, Paula, Stella-Ascariz, Natalia, Bisbal, Otilia, Bermejo-Plaza, Laura, Garcia-Alvarez, Mónica, Alejos, Belén, Hernando, Asunción, Santacreu-Guerrero, Mireia, Cadiñanos, Julen, Mayoral, Mario, Castro, Juan Miguel, Moreno, Victoria, Martin-Carbonero, Luz, Delgado, Rafael, Rubio, Rafael, Pulido, Federico, Arribas, José Ramón

Publikováno v: In eBioMedicine May 2020 55

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.

Autor: Buckley, Rosa De Miguel^1,2 (AUTHOR), Rial-Crestelo, David^2,3 (AUTHOR), Montejano, Rocío^1,2 (AUTHOR), Pinto, Adriana³ (AUTHOR), Jimenez-Gonzalez, María^1,2 (AUTHOR), Lagarde, Maria^2,3,4 (AUTHOR), Esteban-Cantos, Andrés^1,2 (AUTHOR), Aranguren-Rivas, Paula³ (AUTHOR), Cadiñanos, Julen^1,2 (AUTHOR), Bisbal, Otilia^2,3 (AUTHOR), Castro, Juan Miguel¹ (AUTHOR), Santacreu-Guerrero, Mireia³ (AUTHOR), Bermejo-Plaza, Laura³ (AUTHOR), Moreno, Victoria¹ (AUTHOR), Hernando, Asunción^2,3 (AUTHOR), Martín-Carbonero, Luz^1,2 (AUTHOR), Rubio, Rafael^2,3,4 (AUTHOR), Delgado, Rafael^4,5 (AUTHOR), Arribas, José Ramón^1,2,6 (AUTHOR), Pulido, Federico^2,3,4 (AUTHOR) federico.pulido@salud.madrid.org

Publikováno v: Open Forum Infectious Diseases. Nov2022, Vol. 9 Issue 11, p1-4. 4p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Autor: Suárez-García, Inés, Alejos, Belén, Hernando Sebastian, Victoria, Viñuela, Laura, Vera García, Mar, Rial-Crestelo, David, Pérez Elías, María Jesús, Albendín Iglesias, Helena, Peraire, Joaquim, Tiraboschi, Juan, Diaz Franco, Asuncion, Moreno, Santiago, Jarrin-Vera, Inmaculada, Spanish HIV/AIDS Research Network (CoRIS)

Objectives: To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4734::4a1054e8e8290789a31a341e54d56a1d
https://hdl.handle.net/20.500.12105/16142